CollPlant Biotechnologies (CLGN) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
FibroBiologics is the larger company by market cap ($7.9 million vs $6.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLGN | FBLG |
|---|---|---|
| Share price | $3.51 | $1.13 |
| Market cap | $6.64M | $7.86M |
| 1-day change | -11.59% | +1.80% |
| EPS (TTM) | $-9.33 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.80 | $9.98 |
| 52-week low | $2.64 | $0.62 |
| Distance from 52-week high | -86.90% | -88.68% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1006.19% |
| Average volume | 352.86K | 204.44K |
| Shares outstanding | 1.89M | 6.96M |
| Employees | 39 | 15 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CollPlant Biotechnologies
CLGN stock →CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
Health Care · Industrial Specialties · 39 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
CLGN vs FBLG FAQ
Which is bigger, CollPlant Biotechnologies or FibroBiologics?
FibroBiologics (FBLG) is larger, with a market capitalization of $7.86M compared with $6.64M for CollPlant Biotechnologies (CLGN).
Are CollPlant Biotechnologies and FibroBiologics in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for CollPlant Biotechnologies and Biotechnology: Pharmaceutical Preparations for FibroBiologics.